X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/24/2869049/0/en/Cidara-Therapeutics-Announces-Divestiture-of-Rezafungin-to-Mundipharma-to-Focus-on-Advancing-the-Clinical-Development-of-Cloudbreak-DFC-Pipeline.html
https://www.globenewswire.com//news-release/2024/02/12/2827490/0/en/Cidara-Therapeutics-Receives-11-14-Million-Milestone-Payment-Following-European-Approval-of-REZZAYO.html
https://www.globenewswire.com/news-release/2023/12/22/2800553/0/en/Cidara-Therapeutics-Announces-European-Approval-of-REZZAYO-rezafungin-for-the-Treatment-of-Invasive-Candidiasis-in-Adults.html
https://www.globenewswire.com/news-release/2023/12/06/2791705/0/en/Cidara-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-Restore-Trial-of-Rezafungin-in-China.html
https://www.businesswire.com/news/home/20230125005605/en/Cidara-Therapeutics-and-Melinta-Therapeutics-Announce-FDA-Advisory-Committee-Recommends-Approval-of-Rezafungin-for-the-Treatment-of-Candidemia-and-Invasive-Candidiasis
https://www.globenewswire.com/news-release/2022/10/04/2527714/35407/en/Cidara-Therapeutics-Receives-11-1-Million-Milestone-Payment-from-Mundipharma.html
https://www.globenewswire.com/news-release/2022/09/20/2519691/35407/en/Cidara-Therapeutics-Announces-FDA-Acceptance-for-Priority-Review-of-New-Drug-Application-for-Rezafungin-for-the-Treatment-of-Candidemia-and-Invasive-Candidiasis.html
https://www.fiercebiotech.com/biotech/cidara-therapeutics-bags-30m-cash-melinta-licensing-deal-submits-antifungal-fda-review
http://www.pharmafile.com/news/625334/mundipharma-and-cidara-therapeutics-report-positive-phase-iii-results-candidemia-treatme
https://www.globenewswire.com/news-release/2022/04/14/2422689/35407/en/Cidara-Therapeutics-and-Mundipharma-to-Present-Results-from-Global-Phase-3-ReSTORE-Trial-of-Rezafungin-for-the-Treatment-of-Candidemia-and-or-Invasive-Candidiasis-at-ECCMID-2022.html
https://www.forbes.com/sites/danadovey/2020/02/26/new-player-in-the-fight-against-resistant-fungal-infections-in-phase-3-trial/#242e026d34ed
https://www.in-pharmatechnologist.com/Article/2019/09/09/Mundipharma-signs-partnership-deal-for-antifungal
https://www.businesswire.com/news/home/20180925005181/en/FDA-Grants-QIDP-Fast-Track-Designations-Cidara
Market Place
Share 
